MedTrace Logo

Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD

NCT00486772 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2007-06-19

No results posted yet for this study

Summary

Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified.

This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and ED seen in CKD patients.

Conditions

  • Vascular Diseases

Interventions

DRUG

Sevelamer (Renagel), calcium acetate (Phos-ex)

Sponsors & Collaborators

  • Gulhane School of Medicine

    lead OTHER

Principal Investigators

  • Mahmut I Yilmaz · Gulhane School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486772 on ClinicalTrials.gov